Cellular interplay in pulmonary arterial hypertension: Implications for new therapies

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 5, 2014, Pages 885-893

  Nogueira Ferreira, Rita ^a,b   Ferreira, Rita ^a   Henriques Coelho, Tiago ^b  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Endothelial cell; Inflammation; Smooth muscle cell; Thrombosis; Vascular remodeling; Vasoconstriction

Indexed keywords

ENDOTHELIAL CELL; INFLAMMATION; SMOOTH MUSCLE CELL; THROMBOSIS; VASCULAR REMODELING; VASOCONSTRICTION;

HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR;

EID: 84894296768     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.01.030     Document Type: Review

References (128)

1. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010, 121:2045-2066.
2. Wilkins M.R. Pulmonary hypertension: the science behind the disease spectrum. Eur. Respir. Rev. 2012, 21:19-26.
3. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin. Chim. Acta 2009, 403:9-16.
4. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., Elliott C.G., Gaine S.P., Gladwin M.T., Jing Z.C., Krowka M.J., Langleben D., Nakanishi N., Souza R. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54:S43-S54.
5. Schermuly R.T., Ghofrani H.A., Wilkins M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 2011, 8:443-455.
6. Galiè N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., Olschewski H., Peacock A., Pietra G., Rubin L.J., Simonneau G. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur. Heart J. 2004, 25:2243-2278.
7. Ward J.P. Oxygen sensors in context. Biochim. Biophys. Acta 2008, 1777:1-14.
8. Fraisl P., Mazzone M., Schmidt T., Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 2009, 16:167-179.
9. Haga J.H., Li Y.S., Chien S. Molecular basis of the effects of mechanical stretch on vascular smooth muscle cells. J. Biomech. 2007, 40:947-960.
10. Stevens T., Phan S., Frid M.G., Alvarez D., Herzog E., Stenmark K.R. Lung vascular cell heterogeneity: endothelium, smooth muscle, and fibroblasts. Proc. Am. Thorac. Soc. 2008, 5:783-791.
11. Pullamsetti S.S., Savai R., Janssen W., Dahal B.K., Seeger W., Grimminger F., Ghofrani H.A., Weissmann N., Schermuly R.T. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin. Microbiol. Infect. 2011, 17:7-14.
12. Sakao S., Tatsumi K., Voelkel N.F. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir. Res. 2009, 10:95.
13. Urbich C., Dimmeler S. Endothelial progenitor cells. Circ. Res. 2004, 95:343-353.
14. Diller G.-P., Thum T., Wilkins M.R., Wharton J. Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc. Med. 2010, 20:22-29.
15. Wang X.-X., Zhang F.-R., Shang Y.-P., Zhu J.-H., Xie X.-D., Tao Q.-M., Zhu J.-H., Chen J.-Z. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol. 2007, 49:1566-1571.
16. Zhu J.H., Wang X.X., Zhang F.R., Shang Y.P., Tao Q.M., Chen J.Z. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr. Transplant. 2008, 12:650-655.
17. Toshner M., Voswinckel R., Southwood M., Al-Lamki R., Howard L.S., Marchesan D., Yang J., Suntharalingam J., Soon E., Exley A., Stewart S., Hecker M., Zhu Z., Gehling U., Seeger W., Pepke-Zaba J., Morrell N.W. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2009, 180:780-787.
18. Sun C.K., Lin Y.C., Yuen C.M., Chua S., Chang L.T., Sheu J.J., Lee F.Y., Fu M., Leu S., Yip H.K. Enhanced protection against pulmonary hypertension with sildenafil and endothelial progenitor cell in rats. Int. J. Cardiol. 2011, 162:45-58.
19. Ormiston M.L., Deng Y., Stewart D.J., Courtman D.W. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 2010, 43:546-554.
20. Morrell N.W., Adnot S., Archer S.L., Dupuis J., Lloyd Jones P., MacLean M.R., McMurtry I.F., Stenmark K.R., Thistlethwaite P.A., Weissmann N., Yuan J.X.J., Weir E.K. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54:S20-S31.
21. Csortos C., Kolosova I., Verin A.D. Regulation of vascular endothelial cell barrier function and cytoskeleton structure by protein phosphatases of the PPP family. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L843-L854.
22. Burton V.J., Ciuclan L.I., Holmes A.M., Rodman D.M., Walker C., Budd D.C. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 2011, 117:333-341.
23. Lowery J.W., de Caestecker M.P. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 2010, 21:287-298.
24. Cai J., Pardali E., Sanchez-Duffhues G., ten Dijke P. BMP signaling in vascular diseases. FEBS Lett. 2012, 586:1993-2002.
25. Davies R.J., Morrell N.W. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 2008, 134:1271-1277.
26. Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B., Schwalbe E.C., Gruenig E., Janssen B., Koehler R., Seeger W., Eickelberg O., Olschewski H., Gregory Elliott C., Glissmeyer E., Carlquist J., Kim M., Torbicki A., Fijalkowska A., Szewczyk G., Parma J., Abramowicz M.J., Galie N., Morisaki H., Kyotani S., Nakanishi N., Morisaki T., Humbert M., Simonneau G., Sitbon O., Soubrier F., Coulet F., Morrell N.W., Trembath R.C. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 2006, 27:121-132.
27. Atkinson C., Stewart S., Upton P.D., Machado R., Thomson J.R., Trembath R.C., Morrell N.W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002, 105:1672-1678.
28. Teichert-Kuliszewska K., Kutryk M.J.B., Kuliszewski M.A., Karoubi G., Courtman D.W., Zucco L., Granton J., Stewart D.J. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival. Circ. Res. 2006, 98:209-217.
29. Valdimarsdottir G., Goumans M.-J., Rosendahl A., Brugman M., Itoh S., Lebrin F., Sideras P., ten Dijke P. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002, 106:2263-2270.
30. Gangopahyay A., Oran M., Bauer E.M., Wertz J.W., Comhair S.A., Erzurum S.C., Bauer P.M. Bone morphogenetic protein receptor II is a novel mediator of endothelial nitric-oxide synthase activation. J. Biol. Chem. 2011, 286:33134-33140.
31. Xu W., Koeck T., Lara A.R., Neumann D., DiFilippo F.P., Koo M., Janocha A.J., Masri F.A., Arroliga A.C., Jennings C., Dweik R.A., Tuder R.M., Stuehr D.J., Erzurum S.C. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1342-1347.
32. Sehgal P.B., Lee J.E. Protein trafficking dysfunctions: role in the pathogenesis of pulmonary arterial hypertension. Pulm. Circ. 2011, 1:17-32.
33. Sehgal P.B., Mukhopadhyay S. Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs?. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H77-H85.
34. Bonifacino J.S., Glick B.S. The mechanisms of vesicle budding and fusion. Cell 2004, 116:153-166.
35. Mathew R., Huang J., Shah M., Patel K., Gewitz M., Sehgal P.B. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004, 110:1499-1506.
36. Mukhopadhyay S., Xu F., Sehgal P.B. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1373-H1389.
37. Sehgal P.B., Mukhopadhyay S., Xu F., Patel K., Shah M. Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L1526-L1542.
38. Montani D., Chaumais M.C., Guignabert C., Gunther S., Girerd B., Jais X., Algalarrondo V., Price L.C., Savale L., Sitbon O., Simonneau G., Humbert M. Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 2014, 141:172-191.
39. Fuentes A., Coralic A., Dawson K.L. A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. Am. J. Health Syst. Pharm. 2012, 69:1389-1393.
40. Lambert O., Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des. Devel. Ther. 2012, 6:235-244.
41. Seferian A., Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. Eur. Respir. Rev. 2013, 22:217-226.
42. Wu Y., O'Callaghan D.S., Humbert M. An update on medical therapy for pulmonary arterial hypertension. Curr. Hypertens. Rep. 2013, 15:614-622.
43. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galiè N., Ghofrani H.-A., Jansa P., Jing Z.-C., Le Brun F.-O., Mehta S., Mittelholzer C.M., Perchenet L., Sastry B.K.S., Sitbon O., Souza R., Torbicki A., Zeng X., Rubin L.J., Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369:809-818.
44. Ghofrani H.-A., Galiè N., Grimminger F., Grünig E., Humbert M., Jing Z.-C., Keogh A.M., Langleben D., Kilama M.O., Fritsch A., Neuser D., Rubin L.J. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369:330-340.
45. Fujita H., Fukumoto Y., Saji K., Sugimura K., Demachi J., Nawata J., Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010, 25:144-149.
46. Gupta V., Gupta N., Shaik I.H., Mehvar R., McMurtry I.F., Oka M., Nozik-Grayck E., Komatsu M., Ahsan F. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J. Control. Release 2013, 167:189-199.
47. McLaughlin V.V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur. Respir. Rev. 2011, 20:262-269.
48. Rensen S.S., Doevendans P.A., van Eys G.J. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth. Heart J. 2007, 15:100-108.
49. Kawai-Kowase K., Owens G.K. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2007, 292:C59-C69.
50. Hao H., Gabbiani G., Bochaton-Piallat M.-L. Arterial smooth muscle cell heterogeneity. Arterioscler. Thromb. Vasc. 2003, 23:1510-1520.
51. Halayko A.J., Solway J. Invited review: molecular mechanisms of phenotypic plasticity in smooth muscle cells. J. Appl. Physiol. 2001, 90:358-368.
52. Rzucidlo E.M., Martin K.A., Powell R.J. Regulation of vascular smooth muscle cell differentiation. J. Vasc. Surg. 2007, 45:A25-A32.
53. House S.J., Potier M., Bisaillon J., Singer H.A., Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch. 2008, 456:769-785.
54. Hao H., Ropraz P., Verin V., Camenzind E., Geinoz A., Pepper M.S., Gabbiani G., Bochaton-Piallat M.-L. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler. Thromb. Vasc. 2002, 22:1093-1099.
55. Kotani M., Fukuda N., Ando H., Hu W.-Y., Kunimoto S., Saito S., Kanmatsuse K. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc. Res. 2003, 57:265-276.
56. Deguchi J., Namba T., Hamada H., Nakaoka T., Abe J., Sato O., Miyata T., Makuuchi M., Kurokawa K., Takuwa Y. Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Ther. 1999, 6:956-965.
57. Qi Y.X., Jiang J., Jiang X.H., Wang X.D., Ji S.Y., Han Y., Long D.K., Shen B.R., Yan Z.Q., Chien S., Jiang Z.L. PDGF-BB and TGF-{beta}1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1908-1913.
58. Yuan K., Orcholski M., Tian X., Liao X., de Jesus Perez V.A. MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension. Expert Opin. Ther. Targets 2013, 17:557-564.
59. Wang Y., Xue X.Y., Liu Y.X., Wang K.F., Zang X.F., Wang J., Wang P.L., Zhang J., Pan L., Zhang S.Y., Wang J.X. Pulmonary arterial hypertension and microRNAs-an ever-growing partnership. Arch. Med. Res. 2013, 44:483-487.
60. Grant J.S., White K., Maclean M.R., Baker A.H. MicroRNAs in pulmonary arterial remodeling. Cell. Mol. Life Sci. 2013, 70:4479-4494.
61. Courboulin A., Paulin R., Giguere N.J., Saksouk N., Perreault T., Meloche J., Paquet E.R., Biardel S., Provencher S., Cote J., Simard M.J., Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 2011, 208:535-548.
62. Caruso P., MacLean M.R., Khanin R., McClure J., Soon E., Southgate M., MacDonald R.A., Greig J.A., Robertson K.E., Masson R., Denby L., Dempsie Y., Long L., Morrell N.W., Baker A.H. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler. Thromb. Vasc. 2010, 30:716-723.
63. Caruso P., Dempsie Y., Stevens H.C., McDonald R.A., Long L., Lu R., White K., Mair K.M., McClure J.D., Southwood M., Upton P., Xin M., van Rooij E., Olson E.N., Morrell N.W., MacLean M.R., Baker A.H. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ. Res. 2012, 111:290-300.
64. Davis-Dusenbery B.N., Chan M.C., Reno K.E., Weisman A.S., Layne M.D., Lagna G., Hata A. Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J. Biol. Chem. 2011, 286:28097-28110.
65. Burg E.D., Remillard C.V., Yuan J.X. Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br. J. Pharmacol. 2008, 153(Suppl. 1):S99-S111.
66. Fernandez R.A., Sundivakkam P., Smith K.A., Zeifman A.S., Drennan A.R., Yuan J.X. Pathogenic role of store-operated and receptor-operated Ca(2+) channels in pulmonary arterial hypertension. J. Signal Transduct. 2012, 2012:951497.
67. Kuhr F.K., Smith K.A., Song M.Y., Levitan I., Yuan J.X. New mechanisms of pulmonary arterial hypertension: role of Ca(2)(+) signaling. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H1546-H1562.
68. Mandegar M., Yuan J.X.J. Role of K+ channels in pulmonary hypertension. Vasc. Pharmacol. 2002, 38:25-33.
69. Tang B., Li Y., Nagaraj C., Morty R.E., Gabor S., Stacher E., Voswinckel R., Weissmann N., Leithner K., Olschewski H., Olschewski A. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 2009, 41:476-483.
70. Baliga R.S., MacAllister R.J., Hobbs A.J. New perspectives for the treatment of pulmonary hypertension. Br. J. Pharmacol. 2011, 163:125-140.
71. Gupta H., Ghimire G., Naeije R. The value of tools to assess pulmonary arterial hypertension. Eur. Respir. Rev. 2011, 20:222-235.
72. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., Garcia G., Parent F., Herve P., Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
73. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., Beghetti M., Corris P., Gaine S., Gibbs J.S., Gomez-Sanchez M.A., Jondeau G., Klepetko W., Opitz C., Peacock A., Rubin L., Zellweger M., Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009, 30:2493-2537.
74. Prabha M., Jin H.F., Tian Y., Tang C.S., Du J.B. Mechanisms responsible for pulmonary hypertension. Chin. Med. J. (Engl.) 2008, 121:2604-2609.
75. Stenmark K.R., Davie N., Frid M., Gerasimovskaya E., Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda) 2006, 21:134-145.
76. Durmowicz A.G., Parks W.C., Hyde D.M., Mecham R.P., Stenmark K.R. Persistence, re-expression, and induction of pulmonary arterial fibronectin, tropoelastin, and type I procollagen mRNA expression in neonatal hypoxic pulmonary hypertension. Am. J. Pathol. 1994, 145:1411-1420.
77. Papakonstantinou E., Kouri F.M., Karakiulakis G., Klagas I., Eickelberg O. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2008, 32:1504-1512.
78. Aytekin M., Comhair S.A.A., de la Motte C., Bandyopadhyay S.K., Farver C.F., Hascall V.C., Erzurum S.C., Dweik R.A. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L789-L799.
79. Scheibner K.A., Lutz M.A., Boodoo S., Fenton M.J., Powell J.D., Horton M.R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 2006, 177:1272-1281.
80. Ormiston M.L., Slaughter G.R., Deng Y., Stewart D.J., Courtman D.W. The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298:L148-L157.
81. Frisdal E., Gest V., Vieillard-Baron A., Levame M., Lepetit H., Eddahibi S., Lafuma C., Harf A., Adnot S., Dortho M.P. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur. Respir. J. 2001, 18:838-845.
82. Fu L.J., Zhou A.Q., Shen J., Zhao W., Li F. Effect of elastase inhibitor on pulmonary hypertension induced by monocrotaline. Zhonghua Er Ke Za Zhi 2004, 42:375-378.
83. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998, 114:213S-224S.
84. Thompson K., Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J. Cell. Physiol. 1996, 166:495-505.
85. Zaidi S.H., You X.M., Ciura S., Husain M., Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 2002, 105:516-521.
86. Hassoun P.M., Mouthon L., Barberà J.A., Eddahibi S., Flores S.C., Grimminger F., Jones P.L., Maitland M.L., Michelakis E.D., Morrell N.W., Newman J.H., Rabinovitch M., Schermuly R., Stenmark K.R., Voelkel N.F., Yuan J.X.J., Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 2009, 54:S10-S19.
87. Morrell N.W., Archer S.L., Defelice A., Evans S., Fiszman M., Martin T., Saulnier M., Rabinovitch M., Schermuly R., Stewart D., Truebel H., Walker G., Stenmark K.R. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm. Circ. 2013, 3:226-244.
88. Daley E., Emson C., Guignabert C., de Waal Malefyt R., Louten J., Kurup V.P., Hogaboam C., Taraseviciene-Stewart L., Voelkel N.F., Rabinovitch M., Grunig E., Grunig G. Pulmonary arterial remodeling induced by a Th2 immune response. J. Exp. Med. 2008, 205:361-372.
89. Gilfillan A.M., Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 2009, 228:149-169.
90. Banasova A., Maxova H., Hampl V., Vizek M., Povysilova V., Novotna J., Vajnerova O., Hnilickova O., Herget J. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008, 76:102-107.
91. Dahal B.K., Kosanovic D., Kaulen C., Cornitescu T., Savai R., Hoffmann J., Reiss I., Ghofrani H.A., Weissmann N., Kuebler W.M., Seeger W., Grimminger F., Schermuly R.T. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir. Res. 2011, 12:60.
92. Farha S., Sharp J., Asosingh K., Park M., Comhair S.A., Tang W.H., Thomas J., Farver C., Hsieh F., Loyd J.E., Erzurum S.C. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm. Circ. 2012, 2:220-228.
93. Price L.C., Wort S.J., Perros F., Dorfmuller P., Huertas A., Montani D., Cohen-Kaminsky S., Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012, 141:210-221.
94. Selimovic N., Bergh C.H., Andersson B., Sakiniene E., Carlsten H., Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur. Respir. J. 2009, 34:662-668.
95. Hagen M., Fagan K., Steudel W., Carr M., Lane K., Rodman D.M., West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L1473-L1479.
96. Nishimura T., Faul J.L., Berry G.J., Veve I., Pearl R.G., Kao P.N. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am. J. Respir. Crit. Care Med. 2001, 163:498-502.
97. Faul J.L., Nishimura T., Berry G.J., Benson G.V., Pearl R.G., Kao P.N. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am. J. Respir. Crit. Care Med. 2000, 162:2252-2258.
98. Henriques-Coelho T., Oliveira S.M., Moura R.S., Roncon-Albuquerque R., Neves A.L., Santos M., Nogueira-Silva C., La Fuente Carvalho F., Brandao-Nogueira A., Correia-Pinto J., Leite-Moreira A.F. Thymulin inhibits monocrotaline-induced pulmonary hypertension modulating interleukin-6 expression and suppressing p38 pathway. Endocrinology 2008, 149:4367-4373.
99. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114:1417-1431.
100. Zanjani K.S. Platelets in pulmonary hypertension: a causative role or a simple association?. Iran. J. Pediatr. 2012, 22:145-157.
101. Maeda N.Y., Carvalho J.H., Otake A.H., Mesquita S.M.F., Bydlowski S.P., Lopes A.A. Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb. Res. 2010, 125:38-43.
102. Shi G., Morrell C.N. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb. Res. 2011, 127:387-390.
103. Farber H.W., Loscalzo J. Prothrombotic mechanisms in primary pulmonary hypertension. J. Lab. Clin. Med. 1999, 134:561-566.
104. Hirenallur S.D., Detweiler N.D., Haworth S.T., Leming J.T., Gordon J.B., Rusch N.J. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm. Circ. 2012, 2:193-200.
105. Maruyama T., Ohsaki K., Shimoda S., Kaji Y., Harada M. Thromboxane-dependent portopulmonary hypertension. Am. J. Med. 2005, 118:93-94.
106. Humbert M., Montani D., Perros F., Dorfmuller P., Adnot S., Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vasc. Pharmacol. 2008, 49:113-118.
107. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995, 333:214-221.
108. Murray F., MacLean M.R., Pyne N.J. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br. J. Pharmacol. 2002, 137:1187-1194.
109. Pullamsetti S., Kiss L., Ghofrani H.A., Voswinckel R., Haredza P., Klepetko W., Aigner C., Fink L., Muyal J.P., Weissmann N., Grimminger F., Seeger W., Schermuly R.T. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005, 19:1175-1177.
110. Schermuly R.T., Stasch J.-P., Pullamsetti S.S., Middendorff R., Müller D., Schlüter K.-D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H.A., Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 2008, 32:881-891.
111. Seimetz M., Parajuli N., Pichl A., Veit F., Kwapiszewska G., Weisel F.C., Milger K., Egemnazarov B., Turowska A., Fuchs B., Nikam S., Roth M., Sydykov A., Medebach T., Klepetko W., Jaksch P., Dumitrascu R., Garn H., Voswinckel R., Kostin S., Seeger W., Schermuly R.T., Grimminger F., Ghofrani H.A., Weissmann N. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011, 147:293-305.
112. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992, 327:70-75.
113. Tuder R.M., Cool C.D., Geraci M.W., Wang J., Abman S.H., Wright L., Badesch D., Voelkel N.F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1999, 159:1925-1932.
114. Hoshikawa Y., Voelkel N.F., Gesell T.L., Moore M.D., Morris K.G., Alger L.A., Narumiya S., Geraci M.W. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med. 2001, 164:314-318.
115. Robbins I.M., Barst R.J., Rubin L.J., Gaine S.P., Price P.V., Morrow J.D., Christman B.W. Increased levels of prostaglandin D2 suggest macrophage activation in patients with primary pulmonary hypertension. Chest 2001, 120:1639-1644.
116. Kawanabe Y., Nauli S.M. Endothelin. Cell. Mol. Life Sci. 2011, 68:195-203.
117. Rhodes C.J., Davidson A., Gibbs J.S., Wharton J., Wilkins M.R. Therapeutic targets in pulmonary arterial hypertension. Pharmacol. Ther. 2009, 121:69-88.
118. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993, 328:1732-1739.
119. Perros F., Montani D., Dorfmuller P., Durand-Gasselin I., Tcherakian C., Le Pavec J., Mazmanian M., Fadel E., Mussot S., Mercier O., Herve P., Emilie D., Eddahibi S., Simonneau G., Souza R., Humbert M. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 178:81-88.
120. Yi E.S., Kim H., Ahn H., Strother J., Morris T., Masliah E., Hansen L.A., Park K., Friedman P.J. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med. 2000, 162:1577-1586.
121. Berger G., Azzam Z.S., Hoffman R., Yigla M. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr. Med. Assoc. J. 2009, 11:376-379.
122. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F., Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004, 43:13S-24S.
123. Weir E.K., Hong Z., Varghese A. The serotonin transporter: a vehicle to elucidate pulmonary hypertension?. Circ. Res. 2004, 94:1152-1154.
124. Welsh D.J., Harnett M., MacLean M., Peacock A.J. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am. J. Respir. Crit. Care Med. 2004, 170:252-259.
125. Hervé P., Launay J.-M., Scrobohaci M.-L., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 1995, 99:249-254.
126. Dorfmuller P., Zarka V., Durand-Gasselin I., Monti G., Balabanian K., Garcia G., Capron F., Coulomb-Lhermine A., Marfaing-Koka A., Simonneau G., Emilie D., Humbert M. Chemokine RANTES in severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002, 165:534-539.
127. Balabanian K., Foussat A., Dorfmuller P., Durand-Gasselin I., Capel F., Bouchet-Delbos L., Portier A., Marfaing-Koka A., Krzysiek R., Rimaniol A.-C., Simonneau G., Emilie D., Humbert M. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002, 165:1419-1425.
128. Perros F., Dorfmüller P., Souza R., Durand-Gasselin I., Godot V., Capel F., Adnot S., Eddahibi S., Mazmanian M., Fadel E., Hervé P., Simonneau G., Emilie D., Humbert M. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur. Respir. J. 2007, 29:937-943.